Introduction {#s1}
============

Dysmenorrhea is a common health problem among young women \[[@R01]\]. The monthly disability results in 600 million lost working hours and a productivity loss of two billion dollars annually in the United States \[[@R01]\]. A better understanding of the treatment of dysmenorrhea is therefore beneficial for both the affected individuals and their society.

Oral contraceptives (OCs) \[[@R02]\] and progestin \[[@R03]\] have been reported to be effective for the treatment of dysmenorrhea. Some studies have pointed out the risk of thromboembolism associated with the use of hormonal contraceptives \[[@R04]\], while the results concerning the risk have been conflicting across studies \[[@R05]\]. As women who take OC for dysmenorrhea use it for the long term, vascular complications among young women must be seriously considered \[[@R06]\]. In contrast, oral administration of dydrogesterone (DG), the 6-dehydro reversal isomeride of progesterone with molecular structure extremely similar to natural progesterone, at a daily dose between 5 and 60 mg, shows beneficial vascular effects \[[@R03]\] and may have advantages over other progestogen-combined hormonal replacement treatment administered to avoid estrogen-induced adverse effects \[[@R07]\]. Cyclic application of DG has also been shown to induce regular menstruation with symptomatic relief, reduced blood loss, and fewer days of bleeding in women with dysmenorrhea \[[@R03]\].

Biologically, DG treatment reduces reactive oxygen species (ROS) formation \[[@R08]\] and exerts modulating effects on nitric oxide (NO) synthesis and on the expression of endothelial NO synthase (eNOS) \[[@R9]\]. This can be one of the mechanisms of the several beneficial effects of DG. Although the adverse effects of OCs have not yet been elucidated, overproduction of ROS (leading to an increase in oxidative stress) by OCs can be associated with vascular dysfunction \[[@R10]\]. We have previously reported that there were cross-sectionally higher blood levels of diacron reactive oxygen metabolites (d-ROMs: an oxidative stress marker) in women undergoing OC treatment \[[@R11]\], leading to a hypothesis that OC treatment can elevate oxidative stress levels.

While the examination of ROS is sometimes difficult in the clinic setting, a test for d-ROMs has been developed \[[@R12]\]. This test reflects the concentration of hydroperoxides \[[@R12]\] and has been established as a clinically applicable oxidative stress marker \[[@R13]\]. The present study aimed at investigating blood oxidative stress levels, as assessed by the d-ROMs test, in premenopausal women receiving OC and/or DG treatment.

Materials and Methods {#s2}
=====================

Study subjects {#s2a}
--------------

This study was a retrospective cohort design based on our clinic's database (between April 2010 and November 2013). The ethics committee of our institution approved this study and informed consent was obtained from subjects. For avoiding a selection bias, the subjects were chosen from all cases included in the original database. Inclusion criteria were non-pregnant and premenopausal subjects, those who were free from coronary artery disease, cerebrovascular disease, diabetes mellitus, and liver or renal disease, as well as those who were taking any medications, including antioxidant supplements. As the first study cohort, the subjects who complained of primary dysmenorrhea and received OC or DG treatment according to their condition \[[@R02], [@R03]\] during at least a 15-month period were chosen (N = 40). The subjects, who had received OC or DG treatment during the period, included some cases, in whom OC treatment was switched to DG treatment after approximately 6 months of initial OC treatment for the following reasons: headache (N = 1), skin redness (N = 2), and financial issues (N = 4), respectively. As the final study cohort, exclusion criteria were the subjects who had not received blood tests (i.e., parameters related to oxidative stress and inflammation) on at least three-time points (baseline (pre-treatment), 3 months after initial treatment, and approximately 15 months after initial treatment) (excluded subjects: N = 13).

The study cohort ultimately consisted of 27 women (initial OC treatment group: N = 17; initial DG treatment group: N = 10). Among the initial OC treatment group, two subgroups existed as follows: patients with continuous OC treatment (N = 10) and patients with discontinuous OC treatment (as switched from initial OC treatment to DG treatment: N = 7). The data were compared in the initial OC and DG treatment groups between baseline and 3 months after initial treatment (phase 1). Subsequent data were further compared in the subgroups with continuous and discontinuous OC treatment, besides the initial DG treatment group, between 3 months after initial treatment and 15 months after initial treatment (phase 2).

Estimating a sample size for the present study was based on a previous study that examined the difference in the d-ROMs level, a primary outcome, between OC users (mean: 380 Carratelli Unit (Carr U)) and non-users (325 Carr U) \[[@R11]\]. With the power (1-beta level) of 80% at the alpha level of 5% to detect a difference of 55 Carr U of the d-ROMs levels and a standard deviation of 40 Carr U, a sample size of 8 in a group was estimated.

Drugs {#s2b}
-----

In this study, the OC treatment was a triphasic preparation consisting of 21 tablets of 0.035 mg of ethinyl estradiol (EE) and 12 tablets of 0.5 mg of norethisterone (NET) or nine tablets of 1.0 mg of NET. The subjects received the combination of EE and NET for 21 days during each 28-day interval. For the DG treatment, the subjects took DG orally 10 mg/day.

Measurements {#s2c}
------------

All the subjects were interviewed for their medical history, menstruation information and current smoking status. Measurements of body mass index, blood pressure and blood parameters during fasting were taken. Blood was sampled within 2 weeks after menstruation or withdrawal bleeding. As blood parameters, hemoglobin, white blood cell count (WBC), platelet count, hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol (LDL-C), triglycerides, high-density lipoprotein cholesterol (HDL-C), fibrinogen, and high-sensitivity C-reactive protein (hs-CRP) were measured with standard methods in a single laboratory center that is nationally certified (Mitsubishi BCL Laboratory Co. Ltd, Tokyo, Japan). Concerning specific blood parameters of oxidative stress, the d-ROMs test was accomplished by the Free Radical Analytical System (Diacron, Grosseto, Italy) according to the analytical manual \[[@R12]\]. The d-ROMs test unit of measurement is the Carr U and the test shows intra- and inter-assay coefficients of variations of \< 3% \[[@R13]\]. The biological antioxidant potential (BAP) level was determined simultaneously by the system; this test assesses the ability to reduce ferric ions to ferrous ions as an anti-oxidative reaction \[[@R14]\]. The level is expressed as µM \[[@R14]\].

Statistical analysis {#s2d}
--------------------

Comparison of each parameter between the groups was performed with an unpaired *t*-test or Fisher's exact test, and one-way analysis of variance (ANOVA) or two-way (time × group) repeated measure ANOVA. Comparison of pre- and post-data of each parameter within each group was performed with a paired *t*-test. The triglycerides and hs-CRP values were log-transformed in all analyses, due to their skewed distributions. A P value of \< 0.05 was considered significant.

Results {#s3}
=======

Clinical background of the patients in each study cohort group is shown in [Table 1](#T1){ref-type="table"}. There were no obvious differences in the clinical background between the groups with initial OC treatment and initial DG treatment.

###### Clinical Background of Study Subjects

  Parameter                         OC group (N = 17)    DG group (N = 10)    P
  --------------------------------- -------------------- -------------------- ------
  Age, years                        37.5 ± 9.8           41.4 ± 6.1           0.27
  Current smokers, n (%)            2 (12%)              1 (10%)              0.99
  Body mass index, kg/m^2^          20.7 ± 2.5           20.4 ± 2.2           0.73
  Systolic blood pressure, mm Hg    115 ± 18             109 ± 10             0.31
  Diastolic blood pressure, mm Hg   73 ± 13              70 ± 9               0.55
  Hemoglobin, g/dL                  12.9 ± 1.0           11.7 ± 1.8           0.05
  WBC, /µL                          5,688 ± 1,319        5,140 ± 1,088        0.28
  Platelet, × 10^4^/µL              26.1 ± 5.0           29.0 ± 6.6           0.20
  Hemoglobin A1c, %                 4.8 ± 0.2            4.9 ± 0.3            0.31
  LDL-cholesterol, mg/dL            100 ± 31             98 ± 26              0.87
  HDL-cholesterol, mg/dL            75 ± 20              73 ± 10              0.75
  Triglyceride, mg/dL               98 (46 - 159)        77 (55 - 102)        0.57
  Fibrinogen, mg/dL                 275 ± 78             237 ± 27             0.15
  High-sensitivity CRP, mg/dL       0.02 (0.01 - 0.05)   0.01 (0.01 - 0.02)   0.19
  d-ROMs, Carr U                    321 ± 61             356 ± 70             0.19
  BAP, µM                           2,033 ± 179          1,953 ± 191          0.28

OC: oral contraceptive; DG: dydrogesterone; WBC: white blood count; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ROMs: reactive oxygen metabolites; BAP: biological antioxidant potential. Data are presented as means ± standard deviations, medians (interquartile ranges) or subject numbers (%). P \< 0.05 (significance level): comparison between the OC and DG groups by an unpaired *t*-test or Fisher's exact test.

[Table 2](#T2){ref-type="table"} shows the data at baseline and 3 months after initial treatment (phase 1). The d-ROMs level became elevated in the initial OC treatment group (mean: from 321 to 512 Carr U; P \< 0.01), while the d-ROMs level was largely unchanged in the initial DG treatment group (from 356 to 339 Carr U; P = 0.51). The change in the d-ROMs level was significantly different between the two groups. The hs-CRP level also became elevated in the initial OC treatment group (median: from 0.02 to 0.10 mg/dL; P \< 0.01), while the hs-CRP level was largely unchanged in the initial DG treatment group (from 0.01 to 0.01 mg/dL; P = 0.93). The change in the hs-CRP level was significantly different between the two groups. The changes in the other parameters, such as BAP, WBC, platelets, fibrinogen and LDL-C, did not show significant differences between the two groups.

###### Changes in Data From Baseline to 3 Months After Initial Treatment

  Parameter                     Baseline             3 months             P
  ----------------------------- -------------------- -------------------- -------------
  d-ROMs, Carr U                                                          \< 0.01\*\*
    OC group (N = 17)           321 ± 61             512 ± 79             
    DG group (N = 10)           356 ± 70             339 ± 31             
  BAP, µM                                                                 0.21
    OC group (N = 17)           2,033 ± 179          2,029 ± 161          
    DG group (N = 10)           1,953 ± 191          1,970 ± 117          
  High-sensitivity CRP, mg/dL                                             0.01\*
    OC group (N = 17)           0.02 (0.01 - 0.05)   0.10 (0.03 - 0.22)   
    DG group (N = 10)           0.01 (0.01 - 0.02)   0.01 (0.01 - 0.02)   
  WBC, /µL                                                                0.28
    OC group (N = 17)           5,688 ± 1,319        5,994 ± 1,134        
    DG group (N = 10)           5,140 ± 1,088        5,550 ± 1,527        
  Platelet, × 10^4^/µL                                                    0.40
    OC group (N = 17)           26.1 ± 5.0           28.4 ± 7.1           
    DG group (N = 10)           29.0 ± 6.6           29.4 ± 5.5           
  Fibrinogen, mg/dL                                                       0.06
    OC group (N = 17)           275 ± 78             278 ± 68             
    DG group (N = 10)           237 ± 27             234 ± 28             
  LDL-cholesterol, mg/dL                                                  0.75
    OC group (N = 17)           100 ± 31             108 ± 31             
    DG group (N = 10)           98 ± 26              103 ± 24             

OC: oral contraceptive; DG: dydrogesterone; WBC: white blood coun; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ROMs: reactive oxygen metabolites; BAP: biological antioxidant potential. Data are presented as means ± standard deviations or medians (interquartile ranges). \*P \< 0.05, \*\*P \< 0.01: comparison between the OC and DG groups by two-way repeated measure ANOVA.

[Table 3](#T3){ref-type="table"} shows the data at 3 months after initial treatment and at approximately 15 months after initial treatment (phase 2). After approximately 6 months of initial OC treatment, the subgroup with discontinuous OC treatment was switched to DG treatment. The data at 3 months after initial treatment did not significantly differ between the groups with continuous OC treatment, discontinuous OC treatment and DG treatment. Between the subgroups with continuous OC treatment and discontinuous OC treatment, the change in the d-ROMs level was significantly different: namely, the d-ROMs level was reduced in the subgroup with discontinuous OC treatment (mean: from 508 to 372 Carr U; P \< 0.01), while the d-ROMs level was largely unchanged in the subgroup with continuous OC treatment (from 515 to 497 Carr U; P = 0.70). The reduced d-ROMs level in the subgroup with discontinuous OC treatment (mean: 372 Carr U) seemed to be mostly near the baseline d-ROMs level in the OC treatment group (mean: 321 Carr U). The changes in the other parameters, such as BAP, hs-CRP, WBC, platelets, fibrinogen and LDL-C, did not show significant differences between the two subgroups.

###### Changes of Data From 3 to 15 Months After Initial Treatment

  Parameter                          3 months             15 months            P^1^     P^2^          P^3^
  ---------------------------------- -------------------- -------------------- -------- ------------- -------------
  d-ROMs, Carr U                                                               0.04\*   \< 0.01\*\*   \< 0.01\*\*
    Continuous OC group (N = 10)     515 ± 26             497 ± 26                                    
    Discontinuous OC group (N = 7)   508 ± 31             372 ± 32                                    
    DG group (N = 10)                339 ± 31             341 ± 63                                    
  BAP, µM                                                                      0.63     0.20          0.06
    Continuous OC group (N = 10)     2,026 ± 53           1,964 ± 63                                  
    Discontinuous OC group (N = 7)   2,034 ± 63           2,035 ± 75                                  
    DG group (N = 10)                1,970 ± 117          1,865 ± 104                                 
  High-sensitivity CRP, mg/dL                                                  0.58     0.01\*        \< 0.01\*\*
    Continuous OC group (N = 10)     0.05 (0.02 - 0.20)   0.07 (0.03 - 0.11)                          
    Discontinuous OC group (N = 7)   0.15 (0.07 - 0.27)   0.03 (0.02 - 0.08)                          
    DG group (N = 10)                0.01 (0.01 - 0.02)   0.01 (0.01 - 0.02)                          
  WBC, /µL                                                                     0.81     0.33          0.50
    Continuous OC group (N = 10)     6,010 ± 370          5,970 ± 383                                 
    Discontinuous OC group (N = 7)   5,971 ± 443          5,771 ± 457                                 
    DG group (N = 10)                5,550 ± 1,527        5,330 ± 1,667                               
  Platelet, × 10^4^/µL                                                         0.47     0.97          0.44
    Continuous OC group (N = 10)     29.4 ± 2.3           27.8 ± 1.3                                  
    Discontinuous OC group (N = 7)   27.0 ± 2.7           26.3 ± 1.6                                  
    DG group (N = 10)                29.4 ± 5.5           27.6 ± 4.8                                  
  Fibrinogen, mg/dL                                                            0.53     0.34          0.09
    Continuous OC group (N = 10)     256 ± 22             250 ± 20                                    
    Discontinuous OC group (N = 7)   312 ± 31             238 ± 28                                    
    DG group (N = 10)                234 ± 28             232 ± 32                                    
  LDL-cholesterol, mg/dL                                                       0.95     0.66          0.67
    Continuous OC group (N = 10)     107 ± 10             104 ± 9                                     
    Discontinuous OC group (N = 7)   110 ± 12             103 ± 11                                    
    DG group (N = 10)                103 ± 24             99 ± 17                                     

OC: oral contraceptive; DG: dydrogesterone; WBC: white blood count; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ROMs: reactive oxygen metabolites; BAP: biological antioxidant potential. Data are presented as means ± standard deviations or medians (interquartile ranges). \*P \< 0.05, \*\*P \< 0.01: comparison by two-way repeated measure ANOVA. P^1^: between the continuous and discontinuous OC groups; P^2^: between the continuous OC and DG groups; P^3^: between the discontinuous OC and DG groups.

As shown in [Table 3](#T3){ref-type="table"}, the DG treatment group displayed unchanged levels of d-ROMs, BAP, hs-CRP, WBC, platelets, fibrinogen and LDL-C. At 3 and 15 months after initial treatment, the changes in the d-ROMs level and the hs-CRP level were significantly different between the DG treatment group and the subgroup with continuous OC treatment, and between the DG treatment group and the subgroup with discontinuous OC treatment ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The changes in the other parameters, such as BAP, WBC, platelets, fibrinogen and LDL-C, did not show significant differences between the DG treatment group and the continuous or discontinuous OC treatment subgroups.

![Changes of d-ROMs 3 and 15 months after the treatment. OC: oral contraceptive; DG: dydrogesterone; OC-DG: initial OC treatment was switched to DG treatment. Data are presented as means ± standard deviations. P: OC (3 M) versus DG only groups 0 and 3 months after the treatment; P^1^: OC versus DG; P^2^: OC-DG versus DG only groups 3 and 15 months after the treatment by two-way repeated measure ANOVA.](jocmr-10-146-g001){#F1}

![Changes of high-sensitivity CRP 3 and 15 months after the treatment. OC: oral contraceptive, DG: dydrogesterone, OC-DG: initial OC treatment was switched to DG treatment. Data are presented as medians (interquartile ranges). P: OC (3 M) versus DG groups 0 and 3 months after the treatment; P^1^: OC versus DG; P^2^: OC-DG versus DG only groups 3 and 15 months after the treatment by two-way repeated measure ANOVA.](jocmr-10-146-g002){#F2}

There were three current smokers (one in the continuous OC treatment subgroup, one in the discontinuous OC treatment subgroup, and one in the DG treatment group). Their smoking habits did not change during the study period (from baseline to 15 months after initial treatment), even though smoking can generally be a factor potentially associated with oxidative stress and inflammation.

Discussion {#s4}
==========

This study demonstrated that OC treatment increased blood oxidative stress levels in premenopausal women, as measured by the d-ROMs test, a primary outcome measure. Following a previous cross-sectional study that showed a high d-ROMs level in women undergoing OC treatment \[[@R11]\], it would be valuable to demonstrate the finding with OC treatment in a follow-up study. On the other hand, DG treatment did not produce any changes in the oxidative stress level. Notably, when OC treatment was changed to DG treatment, the increased oxidative stress level produced by the OC treatment returned to the baseline level in at least 6 months. This may suggest a possible risk reduction in vascular complications caused by use of OCs. Therefore, it may be important for premenopausal women to switch from OC treatment to DG treatment temporarily to reduce the oxidative burden.

The mechanisms responsible for the increase in oxidative stress by OCs remain unclear, while there are several points to be considered for possible explanations and to discuss further perspectives. The behavior of molecules related to oxidative stress can differ according to the types and doses of estrogen, progestogen, or the particular compounds of estrogen and progestogen. Estrogens are generally known to have various vascular actions by increasing the bioavailability of NO via activation of NO synthase, and NO is inversely related to oxidative stress. However, some differences between estradiol (E2) and EE have been demonstrated, and EE (as used in our current study) seemingly cannot alleviate oxidative stress \[[@R15]\]. NO production and the viability of endothelial cells after exposure to hydrogen peroxide was found to be increased by E2 but not by EE \[[@R15]\], NO production in aortic cells from ovariectomized rats was increased by E2 but reduced with EE \[[@R16]\], and a microarray gene test indicated that the NO synthase-coded gene was down-regulated by OC treatment \[[@R14]\]. Moreover, a clinical study reported that OCs increased the blood levels of oxidative stress markers (e.g., lipid peroxides) and decreased the levels of antioxidant markers (e.g., gamma-tocopherol and beta-carotene) in women \[[@R17]\]. Thus, OC treatment, especially that containing EE, can increase oxidative stress levels.

Concerning treatment with progesterone, its beneficial effects have been shown in the form of improvement of atherogenic lipid profiles \[[@R08]\] and ROS formation (and in turn, oxidative stress production) \[[@R10]\]. However, there is a contradiction in that progesterone can enhance nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and ROS formation \[[@R18]\]. An animal study has demonstrated that conjugated equine estrogen suppresses the development of atherosclerosis, but not in combination with medroxyprogesterone acetate \[[@R19]\]. Medroxyprogesterone acetate could interfere with the vasoprotective effects of estrogens, while this was not observed to happen with natural endogenous progesterone \[[@R19]\]. These results suggest that all progestogens are not equal in terms of their hormonal profiles and actions, for instance, in the abilities of the progestogens to bind to progesterone receptors or to other steroid receptors \[[@R20]\]. One opinion is that progesterone, DG or 17-hydroxyprogesterone caproate are drugs that do not produce some of the adverse effects associated with other progestogens \[[@R20]\], and DG exerts endothelial anti-inflammatory actions (i.e., via a decrease in expression of leukocyte adhesion molecules) \[[@R20]\], perhaps linking with modulation of oxidative stress. Clinical studies have also found that DG treatment could improve oxidative stress conditions in combination with E2 \[[@R21]\]. The DG component offers endometrial protection and cycle control without negating the vasoprotective effects of E2 \[[@R22]\]. Thus, DG treatment may not increase oxidative stress; rather, it may counteract an increase in oxidative stress levels caused by OC treatment \[[@R23]\].

It will be necessary to discuss the types and doses of progestogen in combination with EE in OC treatment, while a progestogen-alone oral preparation is reported to have no adverse effects with respect to vascular complications \[[@R24]\]. Indeed, the MEGA study \[[@R25]\] found that the risk of venous thrombosis was positively associated with estrogen dose and by the type of progestin in combination. However, this finding was not supported by the Danish historical cohort study in that only small differences in the risks of thrombotic stroke and myocardial infarction were observed according to the type of progestin \[[@R06]\]. Progestogen can antagonize the beneficial effects of estrogen by modulating estrogen-induced activation of protein C resistance \[[@R26]\]. Again, progestogen-only drugs were reported to confer no increased risk of venous thromboembolism, when taken in the form of low-dose norethisterone pills, as desogestrel-alone agents, or in the form of hormone-releasing intrauterine devices \[[@R24]\]. In a general sense, progestin-alone treatment is thought to pose little risk of thromboembolism and is recommended for women at high risk of thromboembolism and young women with primary dysmenorrhea who need long-term treatment \[[@R27]\]. Although in OC treatment (including NET) of the present study, the NET-alone effects on oxidative stress levels were not completely evaluated, we think little effects of NET on oxidative stress, even though the effects existed from the above evidence.

To ameliorate this side effect of OCs, the uses of vitamins E and C \[[@R28]\], or products containing green tea catechins \[[@R29]\] were reported to control the oxidative stress generated by OCs. However, we are convinced that temporary replacement of OC with DG treatment is an infallible method for reducing the burden of oxidative stress in women with primary dysmenorrhea.

A follow-up study style was the strength of this study. This study had the limitations. The study design was retrospective, and the study cohort was chosen from subjects in whom all the pertinent test results were available (the tests were not planned beforehand). The sample size was relatively small. Only one measurement method was used to evaluate the blood oxidative stress level. A prospective, larger study or blinded randomized trials with additional oxidative stress measurements is necessary to establish the results of this study. At present, we do not have much evidence of the adverse effects of OCs on vascular dysfunction in association with oxidative stress \[[@R10]\], and future studies may include vascular outcomes. The precise different effects of types and doses of OCs may also be a future debate. Anyhow, more accumulation of data of oxidative stress in DG treatment is necessary for patient care and public health implication.

In conclusion, the present study showed that OC treatment in premenopausal women elevated the oxidative stress level, while DG treatment did not elevate the level. When OC treatment was replaced by DG treatment, the oxidative stress level was reduced. These findings suggest that temporary replacement of OC with DG treatment can attenuate the elevated oxidative stress by OC, thereby alleviating the possible risks of vascular complications induced by OC treatment. Further research is warranted to confirm these findings.
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